Vasopressin V1B Receptor Antagonists as Potential Antidepressants
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Accumulating evidence shows that certain populations of depressed patients have impaired hypothalamus-pituitary-adrenal (HPA) axis function. Arginine-vasopressin (AVP) is one of the primary factors in HPA axis regulation under stress situations, and AVP and its receptor subtype (V1B receptor) play a pivotal role in HPA axis abnormalities observed in depression. Based on this hypothesis, several non-peptide V1B receptor antagonists have been synthesized, and the efficacies of some V1B receptor antagonists have been investigated in both animals and humans. V1B receptor antagonists exert antidepressant-like effects in several animal models at doses that attenuate the hyperactivity of the HPA axis, and some of their detailed mechanisms have been delineated. These results obtained in animal models were, at least partly, reproduced in clinical trials. At least 2 V1B receptor antagonists (TS-121 and ABT-436) showed tendencies to reduce the depression scores of patients with major depressive disorder at doses that attenuate HPA axis hyperactivity or block the pituitary V1B receptor. Importantly, TS-121 showed a clearer efficacy for patients with higher basal cortisol levels than for those with lower basal cortisol levels, which was consistent with the hypothesis that V1B receptor antagonists may be more effective for patients with HPA axis hyperactivity. Therefore, V1B receptor antagonists are promising approaches for the treatment of depression involving HPA axis impairment such as depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Carroll, B. J. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780260017001 · Cited by 2,243
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Stetler, C., & Miller, G. E. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31820ad12b · Cited by 1,123 · cited 1×
“…of the hypothalamus-pituitary-adrenal (HPA) axis is generally acknowledged to occur in a subset of MDD patients (Dinan and Scott, 2005; Stetler and Miller, 2011), and patients with treatment-resistant depression or severe depression tend to show HPA axis dysfunction (Juruena et al., 2009;…”
BackgroundBessa, J. M., Ferreira, D., Melo, I., Marques, F., Cerqueira, J. J., Palha, J. A., Almeida, O. F. X., & Sousa, N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.119 · Cited by 598
Surget, A., Saxe, M., Leman, S., Ibarguen-Vargas, Y., Chalon, S., Griebel, G., Hen, R., & Belzung, C. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.022 · Cited by 556
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471
Regulation of adult neurogenesis by antidepressant treatment
Duman, R. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00358-x · Cited by 463
Purba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433
Aguilera, G., & Rabadan-Diehl, C. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00196-8 · Cited by 375
Ising, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, E. B., Kern, N., Künzel, H. E., Pfennig, A., Uhr, M., & Holsboer, F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.039 · Cited by 341
Glucocorticoids and the Genesis of Depressive Illness a Psychobiological Model
Dinan, T. G. (1994) · British Journal of Psychiatry · doi:10.1192/bjp.164.3.365 · Cited by 339 · cited 1×
“A sustained elevation of HPA activity is considered to be a causal factor in human affective disorders (Dinan, 1994), and irregularities include elevated serum and 24-hour urinary free cortisol, dexamethasone non-suppression (Carroll et al., 1981), a blunted release of adrenocorticotropic hormone…”
BackgroundExtrapituitary expression of the rat V1b vasopressin receptor gene.
Lolait, S. J., O'Carroll, A. M., Mahan, L. C., Felder, C. C., Button, D. C., Young, W. S., Mezey, E., & Brownstein, M. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6783 · Cited by 337
Alonso, R., Griebel, G., Pavone, G., Stemmelin, J., Le Fur, G., & Soubrié, P. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001464 · Cited by 319
Vaccari, C., Lolait, S. J., & Ostrowski, N. L. (1998) · Endocrinology · doi:10.1210/endo.139.12.6382 · Cited by 308
Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression
van Londen, L. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00054-7 · Cited by 306
Scott, L. V., & Dinan, T. G. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00027-7 · Cited by 281
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.656 · Cited by 278
Hernando, F. (2001) · Endocrinology · doi:10.1210/en.142.4.1659 · Cited by 275
The combined dexamethasone/CRH test as a potential surrogate marker in depression
Ising, M., Künzel, H. E., Binder, E. B., Nickel, T., Modell, S., & Holsboer, F. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.014 · Cited by 271
Is the HPA Axis as Target for Depression Outdated, or Is There a New Hope?
Menke, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00101 · Cited by 240 · cited 1×
“However, clinical studies with compounds regulating the HPA axis have not been successful to date (Griebel and Holsboer, 2012; Menke, 2019).”
BackgroundGal, C. S.-L., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrié, P., Nisato, D., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1122 · Cited by 211
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?
Griebel, G., & Holsboer, F. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3702 · Cited by 194
Altemus, M. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820010009002 · Cited by 188
de Goeij, D. C. E., Jezova, D., & Tilders, F. J. H. (1992) · Brain Research · doi:10.1016/0006-8993(92)90552-k · Cited by 181
Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression
Zhou, J.-N., Riemersma, R. F., Unmehopa, U. A., Hoogendijk, W. J. G., van Heerikhuize, J. J., Hofman, M. A., & Swaab, D. F. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.7.655 · Cited by 172
Neuroendocrinological mechanisms of actions of antidepressant drugs
Schüle, C. (2007) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01516.x · Cited by 167
Keck, M. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00351-7 · Cited by 167
O’Keane, V., Frodl, T., & Dinan, T. G. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.03.009 · Cited by 140
Childhood trauma, HPA axis activity and antidepressant response in patients with depression
Nikkheslat, N., McLaughlin, A. P., Hastings, C., Zajkowska, Z., Nettis, M. A., Mariani, N., Enache, D., Lombardo, G., Pointon, L., Cowen, P. J., et al. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.11.024 · Cited by 124
Anxious–Retarded Depression: Relation with Plasma Vasopressin and Cortisol
de Winter, R. F. P., van Hemert, A. M., DeRijk, R. H., Zwinderman, K. H., Frankhuijzen-Sierevogel, A. C., Wiegant, V. M., & Goekoop, J. G. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300002 · Cited by 123
West, D. V., Del‐Favero, J., Aulchenko, Y. S., Oswald, P., Souery, D., Forsgren, T., Sluijs, S., Belkacem, S., Adolfsson, R., Mendlewicz, J., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001420 · Cited by 120
Molecular neurobiology and pharmacology of the Vasopressin/Oxytocin receptor family
Burbach, J. P. H., Burbach, H., Adan, R. A. H., Lolait, S. J., van Leeuwen, F. W., Mezey, É., Palkovits, M., & Barberis, C. (1995) · Cellular and Molecular Neurobiology · doi:10.1007/bf02071318 · Cited by 119
Juruena, M. F., Pariante, C. M., Papadopoulos, A. S., Poon, L., Lightman, S., & Cleare, A. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.050278 · Cited by 114
Stemmelin, J., Lukovic, L., Salome, N., & Griebel, G. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300562 · Cited by 112
Dinan, T. G., & Scott, L. V. (2005) · Journal of Anatomy · doi:10.1111/j.1469-7580.2005.00443.x · Cited by 110
Edwards, S., Guerrero, M. A., Ghoneim, O. M., Roberts, E., & Koob, G. F. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00291.x · Cited by 109
Meynen, G., Unmehopa, U. A., van Heerikhuize, J. J., Hofman, M. A., Swaab, D. F., & Hoogendijk, W. J. G. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.12.010 · Cited by 108
Litvin, Y., Murakami, G., & Pfaff, D. W. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.03.007 · Cited by 104
Vasopressin administration modulates anxiety-related behavior in rats
Appenrodt, E., Schnabel, R., & Schwarzberg, H. (1998) · Physiology & Behavior · doi:10.1016/s0031-9384(98)00119-x · Cited by 99
US Food and Drug Administration approval of esketamine and brexanolone
Cristea, I. A., & Naudet, F. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30292-5 · Cited by 98
Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats
Mlynarik, M., Zelena, D., Bagdy, G., Makara, G. B., & Ježová, D. (2006) · Hormones and Behavior · doi:10.1016/j.yhbeh.2006.12.007 · Cited by 98
Arginine Vasopressin Is Associated with Hypercortisolemia and Suicide Attempts in Depression
Inder, W. J., Donald, R. A., Prickett, T. C. R., FRAMPTON, C. M. A., Sullivan, P. F., Mulder, R., & Joyce, P. R. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00301-6 · Cited by 96
Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder
de Kloet, C. S., Vermetten, E. H. G. J. M., Geuze, E., Wiegant, V. M., & Westenberg, H. G. M. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.11.009 · Cited by 94
Salomé, N., Stemmelin, J., Cohen, C., & Griebel, G. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0424-1 · Cited by 89
Regulation of Pituitary Vasopressin V1b Receptor mRNA during Stress in the Rat
Rabadan‐Diehl, C., Lolait, S. J., & Aguilera, G. (1995) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1995.tb00734.x · Cited by 86
Hodgson, R. A., Higgins, G. A., Guthrie, D. H., Lu, S. X., Pond, A. J., Mullins, D. E., Guzzi, M. F., Parker, E. M., & Varty, G. B. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.12.021 · Cited by 86
Peskind, E. R., Jensen, C. F., Pascualy, M., Tsuang, D. W., Cowley, D. S., Martin, D. C., Wilkinson, C. W., & Raskind, M. A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00053-5 · Cited by 86
Griebel, G., Beeské, S., & Stahl, S. M. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07804 · Cited by 81
Shimazaki, T., Iijima, M., & Chaki, S. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.032 · Cited by 81
Self-citationBlunting of ACTH response to human CRH in depressed patients is avoided by metyrapone pretreatment
von Bardeleben, U., Stalla, G. K., Müller, O. A., & Holsboer, F. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90254-5 · Cited by 81
Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Rosenblat, J. D., McIntyre, R. S., Alves, G. S., Fountoulakis, K. Ν., & Carvalho, A. F. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630175044 · Cited by 76
Koike, H., Iijima, M., & Chaki, S. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.03.017 · Cited by 74
Self-citationSchüle, C., Baghai, T. C., Eser, D., & Rupprecht, R. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.52 · Cited by 73
for the National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group, Ryan, M. L., Falk, D. E., Fertig, J. B., Rendenbach-Mueller, B., Katz, D. A., Tracy, K. A., Strain, E. C., Dunn, K. E., Kampman, K., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.214 · Cited by 72
Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior
Bleickardt, C. J., Mullins, D. E., MacSweeney, C. P., Werner, B. J., Pond, A. J., Guzzi, M. F., Martin, F. D. C., Varty, G. B., & Hodgson, R. A. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1354-x · Cited by 71
Separation-induced ultrasonic vocalization in rat pups: Further pharmacological characterization
Iijima, M., & Chaki, S. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.11.005 · Cited by 70
Self-citationGriffante, C., Green, A., Curcuruto, O., Haslam, C. P., Dickinson, B. A., & Arban, R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706383 · Cited by 64
Overstreet, D. H., & Griebel, G. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.07.021 · Cited by 60
Dinan, T. G., O'BRIEN, S., Lavelle, E., & Scott, L. V. (2004) · Psychological Medicine · doi:10.1017/s0033291703001004 · Cited by 59
Basal cortisol levels in relation to dimensions and DSM-IV categories of depression and anxiety
Veen, G., van Vliet, I. M., DeRijk, R. H., Giltay, E. J., van Pelt, J., & Zitman, F. G. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2009.07.013 · Cited by 58
Zhou, Y., Colombo, G., Carai, M. A. M., Ho, A., Gessa, G. L., & Kreek, M. J. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01532.x · Cited by 57
Iijima, M., Yoshimizu, T., Shimazaki, T., Tokugawa, K., Fukumoto, K., Kurosu, S., Kuwada, T., Sekiguchi, Y., & Chaki, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12699 · Cited by 55
Self-citationLouis, C., Cohen, C., Depoortère, R., & Griebel, G. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301036 · Cited by 55
Oost, T. K., Backfisch, G., Bhowmik, S., van Gaalen, M. M., Geneste, H., Hornberger, W., Lubisch, W., Netz, A., Unger, L., & Wernet, W. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.012 · Cited by 48
Chen, J., Young, S. F., Subburaju, S., Sheppard, J. R., Kiss, A., Atkinson, H. C., Wood, S. A., Lightman, S. L., Gal, C. S., & Aguilera, G. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1410.037 · Cited by 47
Beyond Ketamine: New Approaches to the Development of Safer Antidepressants
Chaki, S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170221101054 · Cited by 44
Self-citationModulation of CRF-R1 mRNA in rat anterior pituitary by dexamethasone: Correlation with POMC mRNA
Zhou, Y., Spangler, R., LaForge, K. S., Maggos, C. E., Ho, A., & Kreek, M. J. (1996) · Peptides · doi:10.1016/0196-9781(96)00014-9 · Cited by 43
Yang, C., Zhang, X., Gao, J., Wang, M., & Yang, Z. R. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.121 · Cited by 43
Non-Monoamine-Based Approach for the Treatment of Depression and Anxiety Disorders
Chaki, S., Okubo, T., & Sekiguchi, Y. (2006) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488906775245318 · Cited by 40
Self-citationKatz, D. A., Locke, C., Greco, N., Liu, W., & Tracy, K. A. (2017) · Brain and Behavior · doi:10.1002/brb3.628 · Cited by 37
Demitrack, M. A., Kalogeras, K. T., Altemus, M., Pigott, T. A., LISTWAK, S. J., & Gold, P. W. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.6.1592871 · Cited by 34
Breuer, M. E., van Gaalen, M. M., Wernet, W., Claessens, S. E. F., Oosting, R. S., Behl, B., Korte, S. M., Schoemaker, H., Gross, G., Olivier, B., et al. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0336-1 · Cited by 34
Iijima, M., & Chaki, S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.12.008 · Cited by 34
Self-citationCorbani, M., Marir, R., Trueba, M., Chafaï, M., Vincent, A., Borie, A. M., Desarménien, M. G., Ueta, Y., Corbani, M., Olma, A., et al. (2017) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2017.10.011 · Cited by 33
Allaman‐Exertier, G., Reymond‐Marron, I., Tribollet, E., & Raggenbass, M. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05866.x · Cited by 31
Dose Response of Arginine Vasopressin to the CCK-B Agonist Pentagastrin
Abelson, J. L., Mellédo, J. L., & Bichet, D. G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00182-2 · Cited by 30
Hodgson, R. A., Mullins, D., Lu, S. X., Guzzi, M., Zhang, X., Bleickardt, C. J., Scott, J. D., Miller, M. W., Stamford, A. W., Parker, E. M., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.02.027 · Cited by 30
Bayerl, D. S., Hönig, J. N., & Bosch, O. J. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.02.020 · Cited by 29
Kamiya, M., Sabia, H. D., Marella, J., Fava, M., Nemeroff, C. B., Umeuchi, H., Iijima, M., Chaki, S., & Nishino, I. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.05.017 · Cited by 28
Self-citationKatz, D. A., Liu, W., Locke, C. S., Dutta, S., & Tracy, K. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4089-5 · Cited by 24
Poretti, M. B., Sawant, R. S., Rask‐Andersen, M., de Cúneo, M. F., Schiöth, H. B., Pérez, M. F., & Carlini, V. P. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4187-4 · Cited by 24
Shekhar, A., Johnson, P. L., Fitz, S. D., Nakazato, A., Chaki, S., Steckler, T., & Schmidt, M. E. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001355 · Cited by 21
Self-citationVarga, J., Fodor, A., Klausz, B., & Zelena, D. (2015) · Amino Acids · doi:10.1007/s00726-015-2034-x · Cited by 20
Makara, G. B., Varga, J., Barna, I., Pintér, O., Klausz, B., & Zelena, D. (2012) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-012-9842-2 · Cited by 20
Hernández‐Pérez, O. R., Crespo‐Ramírez, M., Ferrer, Y. C., Anías-Calderón, J., Zhang, L., Roldán-Roldán, G., Aguilar‐Roblero, R. A., Borroto‐Escuela, D. O., Fuxé, K., & de la Mora, M. P. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4817-0 · Cited by 19
Vasopressin and post-traumatic stress disorder
Sipos, E., Török, B., Barna, I., Engelmann, M., & Zelena, D. (2020) · Stress · doi:10.1080/10253890.2020.1826430 · Cited by 16
High-Contrast PET Imaging of Vasopressin V1B Receptors with a Novel Radioligand, 11C-TASP699
Koga, K., Nagai, Y., Hanyu, M., Yoshinaga, M., Chaki, S., Ohtake, N., Ozaki, S., Zhang, M., Suhara, T., & Higuchi, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.188698 · Cited by 9
Self-citationLetourneau, J. J., Riviello, C. M., Li, H., Cole, A. G., Ho, K.-K., Zanetakos, H. A., Desai, H., Zhao, J., Auld, D. S., Napier, S. E., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.118 · Cited by 8
Napier, S. E., Letourneau, J. J., Ansari, N., Auld, D. S., Baker, J. Α., Best, S. A., Campbell-Wan, L., Chan, J.-H., Craighead, M. W., Desai, H., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.081 · Cited by 7
Napier, S. E., Letourneau, J. J., Ansari, N., Auld, D. S., Baker, J. Α., Best, S. A., Campbell-Wan, L., Chan, R., Craighead, M. W., Desai, H., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.022 · Cited by 7
Novel, potent, selective and brain penetrant vasopressin 1b receptor antagonists
Geneste, H., Bhowmik, S., van Gaalen, M. M., Hornberger, W., Hutchins, C. W., Netz, A., Oost, T. K., & Unger, L. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.07.043 · Cited by 6
TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V1B Receptor
Koga, K., Yoshinaga, M., Uematsu, Y., Nagai, Y., Miyakoshi, N., Shimoda, Y., Fujinaga, M., Minamimoto, T., Zhang, M.-R., Higuchi, M., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232942 · Cited by 3
Self-citationHeuser, I., Bissette, G., Dettling, M., Schweiger, U., Gotthardt, U., Schmider, J., Lammers, C.-H., Nemeroff, C. B., & Holsboer, F. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)8:2<71::aid-da5>3.0.co;2-n
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“Thus far, the antidepressant effects of V1bR antagonists in small clinical trials are mixed but show efficacy signals in patients with overactive HPA activity (22) (Figure 2).”
BackgroundMikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450
“Rodents in which AVP deficiency was observed exhibited reduced depressive and anxiety-like behavior [128].”
BackgroundMethodInfluentialNeuroinflammation—A Crucial Factor in the Pathophysiology of Depression—A Comprehensive Review
Sălcudean, A., Bodo, C.-R., Popovici, R. A., Lica, M. M., Păcurar, M., Crăciun, R.-E., Crișan, A., ENĂTESCU, V. R., Marinescu, I. P., Cîmpian, D. M., et al. (2025) · Biomolecules · doi:10.3390/biom15040502 · Cited by 197
“Conversely, NPY has been shown to exert anxiolytic effects and counteract the effects of stress on the HPA axis, exerting a protective role against stress-induced mood disorders [86,87].”
The HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
“( A higher resolution/colour version of this figure is available in the electronic copy of the article ). blood-brain-barrier [84, 85].”
BackgroundThe cortisol axis and psychiatric disorders: an updated review
George, M. Y., Mageed, S. S. A., Mansour, D. E., & Fawzi, S. F. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00782-x · Cited by 100
“By antagonizing these receptors, V 1B receptor antagonists can potentially reduce cortisol secretion and normalize HPA axis activity [ 135 ].”
Metadata
- Authors
- Chaki, S.
- Affiliations
- Taisho Pharmaceutical (Japan) (JP)
- Corresponding author
- Chaki, Shigeyuki
- ORCID
- Chaki, Shigeyuki
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-03-18
- Volume
- 24
- Issue
- 6
- Pages
- 450-463
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC8278797
- OpenAlex
- W3138981265
- Cited by
- 34
- References
- 95
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 6 · 2022: 3 · 2021: 3
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- depression, hypothalamic-pituitary-adrenal axis, vasopressin, major depressive disorder, basal cortisol, antidepressant efficacy, stress response
- MeSH terms
- Animals, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Humans, Hypothalamo-Hypophyseal System, Receptors, Vasopressin, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.